Navigation Links
Study highlights possible new approach to prostate cancer treatment
Date:8/1/2013

CINCINNATI -- A study in the Journal of Biological Chemistry identifies a new therapeutic approach to treat prostate cancer.

Conducted at Cincinnati Children's Hospital Medical Center, the research shows that expression of the FoxM1 protein is essential for prostate cancer to develop in mouse models. The study appears in the journal's Aug. 2 edition.

The study also shows that depletion of FoxM1 in prostate epithelial cells inhibits tumor cell proliferation, the process by which new blood vessels are formed, and metastasis -- the spread of cancer to other organs of the body.

"It is possible that FoxM1 is important for both cancer initiation and cancer progression," says Tanya Kalin, MD, PhD, a physician-scientist in the division of Pulmonary Biology at Cincinnati Children's and senior author of the study. "Our findings provide the foundation for the development of new therapeutic approaches based on inhibition of FoxM1."

FoxM1 is known to be involved in most solid tumor cancers. Kalin's lab published a study in 2006 showing that increased levels of FoxM1 were associated with the development and progression of prostate cancer in mice. Although the current study focuses primarily on prostate cancer, the findings could also help researchers better understand the pathogenesis of pediatric disease.

In this new study, Kalin and colleagues at Cincinnati Children's studied a novel mouse model of prostate cancer. In this model, loss of FoxM1 decreased tumor growth and metastasis. Without this model, over-expression of FoxM1, either alone or in combination with inhibition of a tumor suppressor known as p19ARF caused a robust proliferation of epithelial cells. This proliferation of cells was not enough to induce progression from proliferation to actual prostate cancer, but it caused small prostate epithelial tubes to shrink.


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Page: 1

Related biology news :

1. Breath analysis reliably indicates presence, level of infection in mice, UCI study finds
2. Southerners are less trusting, but trust is a factor in environmental cooperation, study shows
3. Study investigates extraordinary trout with tolerance to heavily polluted water
4. Extinct ancient ape did not walk like a human, study shows
5. Study explains Pacific equatorial cold water region
6. Study finds depletion of alveolar macrophages linked to bacterial super-infections
7. New study finds nighttime heat waves increasing in Pacific Northwest
8. Study finds missing piece of pediatric cancer puzzle
9. Its not just the heat -- its the ozone: Study highlights hidden dangers
10. LSUHSC researcher awarded NCI grant to study link between chronic inflammation and cancer
11. Healthrageous, United BioSource And Boehringer Ingelheim Launch SMART Digital Diabetes Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the ... ("ILC") 2017 of the European Association for the Study of ... the positive effects of PBI-4050 on reduction of non-alcoholic steatohepatitis ... ... Gagnon, Vice-President of R&D Pre-clinical of Prometic "This extensive preclinical ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader in ... today that they were named one of the 2017 Top 10 eClinical Trial ... in the pharmaceutical industry. , “We take pride in honoring Parallel6 as one of ...
(Date:4/20/2017)... Dutch philosopher Koert van Mensvoort - founder of the Next Nature ... Eindhoven - has written a ,Letter to Humanity, in support of ... becoming a slave and victim to its own technology, but to employ technology ... ... Mensvoort – founder of the Next Nature Network and Fellow of ‘Next Nature’ ...
(Date:4/20/2017)... -- For today, Stock-Callers.com redirects investors, attention to ... clinical research aimed at treating diseases and medical conditions. Under ... Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM ... our complimentary research reports on these stocks now at: ... http://stock-callers.com/registration ...
Breaking Biology Technology: